New Update. Impressive speed of results for E. coli
Update: NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli limited abstract
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Novel Immunoassay for E coli O157:H7
Researchers: Classified until June 2017
Introduction: E. coli O157:H7 is associated with enterohemorrhagic infections, and is a concern for healthcare providers, food-handlers, and daycare providers. Rapid identification of this pathogen is critical in cases of outbreaks, and empirical treatment with broad-spectrum antibiotics may lead to more severe disease. We have developed an assay that allows for the simultaneous identification of E. coli O157:H7 and determination of its antibiotic susceptibility.
Methods: N-ASSAY
Methods Details Classified until June 2017
Results: O157:H7 was detected at and above 10^6 bacteria/ml following a 30-minute incubation, with no interference by other tested bacteria. By increasing the incubation time to 6 hours, the sensitivity of the test increased to 10^1 bacteria/ml. In addition, incubation with ceftriaxone during this six-hour time period showed inhibition of growth.
Summary: This assay allows for the rapid detection of a high inoculum of E. coli O157:H7, and sensitivity is increased following a six-hour incubation. Importantly, antibiotic susceptibility may be determined during this six-hour incubation.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B
Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
